NCT04682210

Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection

A Phase III, Randomized, Open-lable, Multi Center Study of Sintilimab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Curative Hepatic Resection

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 246 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, multi-center, randomized, controlled phase III study, to evaluate the efficacy and safety of sintilimab plus bevacizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after radical resection

Detailed description

There is no stardard adjuvant treatment for HCC. This study is to to evaluate the efficacy and safety of sintilimab plus bevacizumab as adjuvant therapy in HCC patients who are at high risk of recurrence after radical resection.

Conditions

• HCC
• Adjuvant Therapy
• Immunotherapy

Interventions

Type	Name	Description
DRUG	Sintilimab	Sintilimab 200mg IV Q3W
DRUG	Bevacizumab	Bevacizumab 7.5mg/kg IV Q3W

Timeline

• Start date: 2020-12-01
• Primary completion: 2023-12-01
• Completion: 2024-12-01
• First posted: 2020-12-23
• Last updated: 2020-12-23

Locations

1 site across 1 country: China